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SYNAPTIC NEUROSCIENCE
Spliceosomal proteins recognize consensus cis-regulatory motifs, 
located in introns or exons, and subsequently govern the inclu-
sion or exclusion of exons in the mature mRNA end-product. 
Pathogenic mutations often disrupt regulatory cis-binding splice 
motifs within known risk genes, resulting in aberrant splicing, and 
manifestation of the disease phenotype. Genetic, epigenetic, or 
environmental factors can also affect the capacity of trans-acting 
splice factors and produce aberrant splicing patterns contribut-
ing to disease. Figure 1 portrays an example of the relationship 
between trans- and cis-acting factors during alternative splicing. 
Global estimates based on mathematical models suggest up to 
60% of all disease-causing mutations disrupt splicing in cis or 
trans (Lopez-Bigas et al., 2005; Wang and Cooper, 2007). When 
individual genes are assayed for disease-causing mutations, up 
to 50% of pathogenic mutations affect splicing, largely through 
cis-acting mechanisms. (Mayer et al., 1999, 2000; Teraoka et al., 
1999; Ars et al., 2000; Messiaen et al., 2000; Cartegni et al., 2002; 
Pagenstecher et al., 2006).
Messenger RNA transcribed from CAM genes is extensively 
spliced to produce unique protein end-products necessary for spe-
cialized cell-to-cell interactions (Shapiro et al., 2007). In the central 
nervous system, alternative splicing of CAMs is associated with syn-
apse maturation and the neurotransmitter to be used for synaptic 
signaling. For example, trans-synaptic binding of α-neurexin to 
neuroligin is determined by the expression of a neuroligin spliceo-
form lacking a critical N-glycosylation site that blocks α-neurexin 
binding (Boucard et al., 2005). In turn, interactions between these 
trans-synaptic binding partners determines phenotypic fate of 
maturing neuronal synapses, either toward excitatory glutamater-
gic or inhibitory gamma-aminobutyric acid (GABA)ergic signal-
ing (Chih et al., 2006). Gene expression differences between ASD 
IntroductIon
Genome-wide association studies, analyses of copy number vari-
ants, DNA sequencing approaches, and familial linkage studies have 
revealed a number of autism risk genes encoding cellular adhesion 
molecules (CAMs) and synaptic scaffold proteins (for review, see 
Betancur et al., 2009). These include the neurexin, neuroligin, con-
tactin, and cadherin gene families, members of the general immu-
noglobulin CAM superfamily, and SH3 and multiple ankyrin repeat 
domain proteins (SHANK). Subsequent attempts to find single 
nucleotide polymorphisms (SNPs) conferring risk within CAM and 
scaffold genes have revealed few disease-causing coding variants 
shared among affected individuals (Vincent et al., 2004; Gauthier 
et al., 2005, 2009; Yan et al., 2005, 2008; Ylisaukko-oja et al., 2005; 
Blasi et al., 2006; Feng et al., 2006; Durand et al., 2007; Berkel et al., 
2010). These sequencing studies focused exclusively on protein-
coding regions and adjacent constitutive splice sites, driven by the 
assumption that the pathogenic mutations are deleterious amino 
acid substitutions in these synaptic proteins. More recently, how-
ever, increased understanding of RNA biology continues to reveal 
mechanisms by which RNA processing defects cause or contribute 
to disease phenotypes in humans, especially in neurodegenerative 
and neuromuscular disorders, where dysfunctional RNA splicing 
is prominent (Cooper et al., 2009).
Under normal conditions, constitutive and alternative splic-
ing is directed by a nuclear protein aggregate of more than 100 
core proteins and secondary modulators, collectively known as 
the spliceosome, which interacts with heterogeneous nuclear RNA 
[hnRNA or pre-messenger RNA (pre-mRNA)] in a process highly 
conserved in eukaryotes (Zhou et al., 2002). This process produces 
tissue-specific RNA and protein isoforms that can vary throughout 
development or in response to synaptic activity (Li et al., 2007). 
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doi: 10.3389/fnsyn.2011.00001(AchE)-like domain in neuroligin mRNA transcripts mediates 
the affinity of the translated neuroligin protein to α-neurexins, 
which subsequently determines the neurotransmitter phenotype 
at the synapse (Boucard et al., 2005; Chih et al., 2006). The AchE-
like domain is also crucial for neuroligin dimerization (Comoletti 
et al., 2003; Fabrichny et al., 2007). One study to date has examined 
neuroligin mRNA spliceoform expression in lymphoblastoid cell 
lines derived from autistic patients, revealing atypical splicing 
for neuroligin 3 (NLGN3) and X-linked neuroligin 4 (NLGN4X; 
Talebizadeh et al., 2006). One of 10 autistic samples lacked a trun-
cated isoform of NGLN3, in which exon 7 is spliced out, that was 
present in all other samples and in female control brain tissue. A 
second patient from the autism cohort expressed a novel NLGN4X 
spliceoform lacking exon 4. The alternatively spliced exon for 
each of these spliceoforms encodes a portion of the AchE-like 
domain, potentially impacting dimerization and neurexin bind-
ing. However, the function of the constitutively expressed NLGN3 
truncated isoform is unknown and no functional analyses were 
preformed for NLGN4X.
A second study, examining calcium-dependent secretion acti-
vator 2 (CADPS2) mRNA expression in autistic patient blood 
samples, noted expression of a novel splice variant lacking exon 
3 in 4 of 16 autistic patients, but was not in 24 control samples 
(Sadakata et al., 2007a). However, a second independent labora-
tory found no difference between expression patterns of ASD and 
control patients, with both cohorts displaying a subset of samples 
expressing both isoforms (Eran et al., 2009). A significant difference 
between relative quantities of the two spliceoforms across the two 
studies is noted as a possible contributor to the discrepant results 
(Eran et al., 2009, authors reply). CADPS2 plays a crucial role in 
neuronal development through its modulation of brain-derived 
neurotrophic factor (BDNF) release and signaling properties at 
the synapse. Significant reductions in axonal CADPS2 transport 
for the novel spliceoform results in decreased CADPS2-mediated 
BDNF release (Sadakata et al., 2007a). Similarly, Cadps2 knockout 
mice have decreased BDNF release and significant morphological 
changes of cerebellar Purkinje cells (Sadakata et al., 2007b).
patients and controls – measured with microarrays – emphasize 
gene splicing and cellular adhesion as biological processes contrib-
uting to ASD (Abrahams and Geschwind, 2008).
At present, few studies have systematically examined CAM splic-
ing in ASD, especially in tissues germane to the disorder, but atypical 
splicing patterns have been observed in autistic patients for at least 
five genes with significant synaptic functions (CADPS2, NLGN3, 
NLGN4X, NRXN1, and SHANK3). In addition, mutations affect-
ing splicing have been frequently identified as pathogenic in genes 
responsible for some forms of syndromic autism (TSC1, TSC2, 
and NF1). Still other genes associated with syndromic autisms 
encode multifunctional proteins that have some capacity to per-
form alternative splicing in a trans-acting fashion (FMR1, MECP2, 
and SNRPN). With evidence for aberrant splicing accumulating in 
a multitude of other neurological disorder, it is prudent to critically 
review early splicing findings in ASD to determine whether similar 
dysfunctional processes are underlying ASD etiology or modifying 
autistic-like behaviors.
AtypIcAl SplIce VArIAnt expreSSIon
In humans, genetic variants that change or delete amino acid cod-
ing regions in NLGN3 or NLGN4 are sufficient to produce autistic 
phenotypes (Jamain et al., 2003; Laumonnier et al., 2004; Lawson-
Yuen et al., 2008; Pampanos et al., 2009). One likely functional 
consequence of these mutations at the synaptic level, based on 
animal and in vitro human studies, is an imbalance in homeo-
static glutamatergic, and GABAergic signaling (Chih et al., 2005; 
Chubykin et al., 2007; Tabuchi et al., 2007; Hines et al., 2008; 
Huang and Scheiffele, 2008; Blundell et al., 2009; Gibson et al., 
2009). Neuroligins are crucial for synapse maturation, but not 
central to the actual formation of synapses. Neuroligin knockout 
mice, even triple knockouts for Nlgn1, Nlgn2, and Nlgn3, show no 
significant change in the total number of synapses formed, but the 
signaling intensity at formed glutamatergic and GABAergic syn-
apses is reduced considerably, relative to wild-type animals, lead-
ing to respiratory failure, and early postnatal death (Varoqueaux 
et  al.,  2006).  Alternative  splicing  of  the  acetylcholinesterase 
FiguRe 1 | Factors in alternative splicing. (A) Under normal conditions, 
trans-acting splice factors bind cis-regulatory sequences (in introns or exons), 
resulting in typical patterns of spliceoform expression. (B) Genetic or epigenetic 
disruption of trans-acting splice factor alters the overall amount, activity, or affinity 
for the cis-regulatory sequence, resulting in changes in spliceoform quantities for 
multiple target RNAs. (C) Mutation in regulatory cis-binding sequence disrupts 
consensus binding site for trans-acting splice factor. This can result in quantitative 
or qualitative changes in spliceoform expression of a single target RNA.
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tic patients and 192 controls by sequencing coding regions and 
adjacent splice junctions. This study yielded five autism-specific 
mutations within NRXN1, one of which disrupted the five’ splice-
donor site following exon 4. Although the effect on mRNA expres-
sion is not confirmed in this study, the splice-donor site mutation 
could produce an effect similar to that observed for SHANK3, in 
which a frame shift compels use of a cryptic downstream splice site 
resulting in nonsense-mediated mRNA decay or a dysfunctional 
NRXN protein. A frame shift at exon 4 is predicted to disrupt the 
majority of the laminin neurexin sex hormone-binding protein 
(LNS) domains and epidermal growth factor (EGF)-like calcium 
binding domain. During synapse maturation, the sixth LNS domain 
is alternatively spliced to mediate GABAergic (Boucard et al., 2005; 
Kang et al., 2008) or glutamatergic postsynaptic development (Ko 
et al., 2009).
Sequencing  efforts,  like  those  put  forth  for  SHANK3  and 
NRXN1, are crucial for identifying candidate mutations, although 
the focus on protein-coding mutations has yielded very few can-
didates unique to autism. Newer high-throughput sequencing 
technologies  allow  researchers  to  expand  their  search  beyond 
the exome and detect intronic or intragenic mutations that also 
have the potential to contribute to ASD etiology. Still, estimating 
the contribution of any variant to ASD phenotype remains an 
  important consideration.
Similar to the SHANK3 and NRXN1 mutations described above, 
gene-linked mutations that disrupt splicing are core components 
of tuberous sclerosis (TSC) and neurofibromatosis type 1 (NF-1), 
which contribute to syndromic ASD diagnoses. Mutations in one 
of two genes, TSC1 encoding hamartin or TSC2 encoding tuberin, 
cause TSC (Narayanan, 2003), while NF-1 results from a muta-
tion in the neurofibromin 1 gene (NF1), usually producing a dys-
functional truncated protein (Heim et al., 1994). Loss of any one 
of these three genes is sufficient to alter neuron morphology (Li 
et al., 2001; Tavazoie et al., 2005; Hsueh, 2007) and perturb gluta-
matergic and GABAergic signaling (Husi et al., 2000; Costa et al., 
2002; von der Brelie et al., 2006). Two separate studies examining 
mutations in TSC1 and TSC2 revealed a high proportion of patho-
genic splice-site mutations that introduce premature stop codons 
and truncate the predicted protein sequence, disrupting normal 
function (Mayer et al., 1999, 2000). Similarly, cDNA screens of 
NF-1 patients reveal that splice-site mutations constitute the most 
common type of mutation causing NF-1, occurring in 28–50% of 
patients (Ars et al., 2000; Messiaen et al., 2000). Despite the high 
incidence of splice-site mutations in these three genes, the relation-
ship between misspliced mRNA transcripts and ASD diagnosis 
remains to be investigated.
SyndromIc ASd GeneS AS Trans-ActInG SplIce 
modulAtorS
To this point, we have focused on cis-acting splice-site mutations 
that are potentially contributing to ASD. Here we focus on four 
multifunctional trans-acting proteins that contribute to syndromic 
ASDs that also demonstrate some capacity to perform alternative 
splicing. For these proteins, we note that alternative splicing is but 
one of their demonstrated functions and not necessarily driving 
the autistic phenotype.
tISSue SelectIVIty of SplIcInG proceSSeS
Important caveats need to be considered when drawing conclu-
sions from the two aforementioned studies. First, no mutation was 
identified in any of the surveyed genes to explain the splicing dif-
ferences, despite exon sequencing of NLGN3 and NLGN4X in the 
affected patients. Therefore, it is not clear whether these spliceo-
forms are the result of cis-acting genetic variants in unsequenced 
intronic regions or mutations that affect trans-acting splice factors. 
Second, the mRNA examined in each of these studies originated 
from peripheral blood tissues; either actively growing lymphoblast-
oid cell lines (Talebizadeh et al., 2006) or whole blood homogenates 
(Sadakata et al., 2007a). Global patterns of gene expression can 
substantially differ in these peripheral tissues, necessarily driving 
tissue differentiation and associated specialized tissue functions 
in the central nervous system. Even the media in which cells are 
cultured can contribute to isoforms-specific expression of splic-
ing factors, which then have pleiotropic effects on downstream 
RNA targets (Lee et al., 2009). An unexpected spliceoform seen 
in blood tissues could be constitutively expressed in other tissues; 
such is the case with the CADPS2 truncated variant in the cer-
ebellum versus blood (Eran et al., 2009). Furthermore, although 
reduced BDNF release was observed for the truncated version of 
CADPS2, no causative roles for the aberrant spliceoforms have been 
established in ASD. Therefore, caution must be exercised when 
extrapolating expression patterns observed in cultured tissues or 
whole blood to other tissues.
Gene-lInked mutAtIonS dISruptInG SplIcInG And 
SynApSe functIon
Mutations in cis-regulatory splice sites can disrupt the splic-
ing process (Figure 1C), especially when present in consensus 
splice-donor, acceptor, or polypyrimidine branch sites recog-
nized by the core components of the spliceosome. Exhaustive 
sequencing of two genes intimately linked to synaptogenesis, 
SHANK3 and NRXN1, uncovered rare splice-site mutations in 
ASD patients. For SHANK3, the protein-coding regions and 
flanking splice junctions from 427 ASD subjects and 190 controls 
were sequenced, revealing five novel non-synonymous variants 
and one splice-site mutation (Gauthier et al., 2009). Of these 
novel variants, only two were unique to autism, including the 
splice-site mutation characterized by the deletion of a guanine 
nucleotide crucial for definition of the splice-donor site preced-
ing exon 19. Analysis of parental DNA suggests this mutation 
appeared de novo. This splice-site mutation produced a measur-
able change in gene expression, resulting in a longer transcript 
through  the  use  of  a  cryptic  downstream  splice-donor  site, 
confirmed by examining lymphoblast mRNA from this patient. 
Microdeletion  or  translocation  of  the  chromosomal  domain 
harboring SHANK3 (22q13.3) results in a consistent pheno-
type (Bonaglia et al., 2001, 2006), in which affected individuals 
often present with autistic-like behaviors (Cusmano-Ozog et al., 
2007). During synaptogenesis, SHANK3 protein recruits essential 
glutamatergic components to the synapse, resulting in a greater 
number of functional synapses and increased excitatory signaling 
(Roussignol et al., 2005). More recently, exon sequencing also 
revealed protein-coding mutations in SHANK2 related to ASD 
and mental retardation (Berkel et al., 2010).
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and is responsible for constitutive RNA splicing (Horn et al., 1992). 
SNRPN and some specific snoRNAs are primarily expressed in 
neurons (Schmauss et al., 1992), suggesting a tissue-specific role in 
modulating gene expression and splicing, but no specific relation-
ship to CAM splicing has been demonstrated.
Finally, the gene encoding RNA binding protein, FOX-1 homolog 
1 (RBFOX1; also known as A2BP1 and FOX1) was found to be par-
tially translocated and deleted in an autistic female patient (Martin 
et al., 2007; Sebat et al., 2007). In vertebrates, FOX-1 acts as a tis-
sue-specific splicing regulator (Jin et al., 2003; Underwood et al., 
2005) by binding pre-mRNA and preventing the formation of the 
spliceosomal early “E” complex (Fukumura et al., 2007; Zhou and 
Lou, 2008). Depending on the proximity of the FOX-1 protein to an 
alternative exon, it promotes either inclusion or exclusion of the tar-
get exon (Underwood et al., 2005). Analogous function in humans 
is inferred from the conserved binding properties of the human 
protein to specific cis-regulatory elements in RNA (Ponthier et al., 
2006) that are spatially conserved in the human genome surround-
ing brain-specific alternative exons (Minovitsky et al., 2005), and 
the ability of the murine protein to direct the alternative splicing of 
human genes in vitro (Fukumura et al., 2007; Zhou and Lou, 2008). 
Apart from autism, de novo translocation/deletions of this gene have 
been associated with epilepsy and mental retardation (Bhalla et al., 
2004). The extensive network of candidate genes targeted by FOX-1 
includes the autism-associated genes NLGN3, NLGN4X, NRCAM, 
NRXN1, and PCDH9 (Zhang et al., 2008), supporting observations 
of diverse disease phenotypes when mutated.
At present, a role for trans-acting factors contributing to ASD 
through their alternative splicing capabilities is unsubstantiated. 
Two major questions need resolved before the role of these trans-
acting factors in autism can be properly evaluated. First, do these 
proteins act upon ASD risk genes as splice factors in vivo? Second, 
even if they are shown to interact with RNA transcribed from risk 
genes to direct alternative splicing, is this relationship relevant 
to the manifestation of the disorder? Methods such as UV-based 
protein-RNA crosslinking, coupled with ultra high-throughput 
sequencing (Licatalosi et al., 2008) are available to begin answer-
ing these questions.
dIScuSSIon
Identifying novel ASD risk genes remains an ongoing endeavor. As 
more susceptibility genes are verified, accumulating evidence sug-
gests a critical role for disrupted synaptic signaling due to genetic 
mutations  in  CAMs.  Observations  of  frequent  and  necessary 
alternative splicing of CAMs in synaptic signaling, coupled with a 
greater appreciation for the role RNA processing defects in disease, 
demands a critical review of early findings in autism. Studies where 
mutations were uncovered in cis-regulatory splice sites (SHANK3, 
NRXN1, TSC1, TSC2, and NF1) and characterizations of aberrant 
mRNA expression from autistic patients (NLGN3, NLGN4X, and 
CADPS2) support the possibility that splicing defects can contrib-
ute to autism, while more evidence is required to determine the 
splicing capacity of trans-acting ASD risk proteins (FMRP, MECP2, 
SNRPN, and FOX-1) and subsequent effects related to ASD behav-
iors or etiology. Genetic variants that cause aberrant splicing can fill 
part of the missing heritability in ASD, but this question remains 
Fragile X syndrome is responsible for approximately 2% of all 
ASD cases (Zafeiriou et al., 2007). The affected protein in fragile 
X (FMRP) contains a KH-type RNA binding domain that associ-
ates with structural “kissing complex” motifs present in the target 
mRNAs, which prevents polyribosome binding, thereby gating 
activity-dependent  protein  translation  at  the  synapse  (Darnell 
et al., 2005). Mutations within this domain can result in a mental 
retardation phenotype (De Boulle et al., 1993). FMRP can also bind 
RNAs containing structural motifs known as guanine(G)-quartets 
(Darnell et al., 2001) through which it acts as a splicing modulator 
in vitro (Didiot et al., 2008). The possibility that FMRP contributes 
to RNA splicing, in addition to its well-validated role in protein 
translation, is an attractive hypothesis that would add an addi-
tional layer of regulatory function to the repertoire of FMRP. The 
FMRP isoform responsible for translation regulation is located in 
the cytoplasm (Khandjian et al., 2004), but alternative splicing of 
FMR1 can result in nuclear localization of the protein (Sittler et al., 
1996). In mouse, FMRP interacts with mRNA transcribed from 
neuroligin genes NLGN1 and NLGN2 in vivo, and FMRP null mice 
have reduced NLGN1 but not NLGN2 protein levels, suggesting a 
role of FMRP in NLGN1 translation (Dahlhaus and El-Husseini, 
2010). However, the significance of FMRP on neuroligin transcript 
splicing remains to be investigated, especially considering that the 
capacity for FMRP to perform splicing has only been demonstrated 
in vitro on RNA transcribed from the fragile X gene (FMR1; Didiot 
et al., 2008).
Behavioral overlap exists between autism and Rett syndrome 
(Mount et al., 2003), but the presence of a causative genetic muta-
tion precludes ASD diagnosis for this pervasive developmental dis-
order. The affected gene, MECP2, is also implicated as an ASD risk 
gene through haplotype analysis in families with autistic probands 
(Loat et al., 2008). MECP2 is most frequently studied for its role in 
epigenetic transcriptional repression, but it also binds RNA with 
high affinity via its RNA binding domains (Bienvenu and Chelly, 
2006), through which MECP2 can act as an alternative splicing 
regulator in vitro (Young et al., 2005). In MeCP2 null mice, aberrant 
splicing patterns are observed for brain-expressed genes (Young 
et al., 2005), although it is not clear whether this is the direct results 
of MECP2 on RNA splicing or an indirect result of MECP2 acting as 
a transcriptional regulator of other undetermined splice factors.
Prader–Willi syndrome is a genetically complex disorder typi-
cally resulting from de novo deletion of paternally inherited genes 
on chromosomal region 15q13-11. Most notably, affected genes 
include the SNURF–SNRPN complex and small nucleolar RNAs 
(snoRNAs) also encoded within SNRPN. The snoRNAs encoded 
within SNRPN regulate the expression of the anti-sense encoded 
UBE3A (Runte et al., 2004), which is particularly significant given 
the gene-dose dependent effect of this region on autistic pheno-
types; i.e., maternal uniparental disomy results in greater incidence 
of ASD (Veltman et al., 2004). The protein encoded by UBE3A 
localizes to synapses in cerebellar Purkinje cells and pyramidal 
neurons of the hippocampus and cortex where it contributes to 
dendritic spine development (Dindot et al., 2008). At least one 
snoRNA encoded in SNRPN, HBII-52, directs alternative splic-
ing of numerous target genes (Kishore et al., 2010), including the 
serotonin 2C receptor (Kishore and Stamm, 2006). In addition to 
snoRNAs, the protein encoded by SNRPN is a member of the small 
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regions that regulate the transcription and processing of the risk 
gene RNAs. Understanding the genetic mechanisms contributing 
to a phenotype (i.e., increased versus decreased expression of any 
given spliceoform) provides a strong basis for forming hypotheses 
about the microenvironment where the expressed gene has influ-
ence, and eventually even hypotheses about entire biological systems 
or neural circuits. Furthermore, in highly heritable disorders, the 
most immediate phenotype resulting from a genetic mutation is 
observable at the RNA level. Examining more distant phenotypes to 
uncover genetic contributions to ASD, such as complex behaviors, 
introduces more opportunity for environmental influence, conse-
quently diluting the ability to detect subtle genetic factors.
Sequence variants that affect splicing quantitatively or those 
producing an unexpected novel spliceoform expressed at low levels 
are difficult to detect, especially when expressed in discrete cell 
types. Even when the unique spliceoforms are known, measur-
ing their expression requires tissues relevant to the disorder from 
affected individuals. To that end, the Autism Tissue Program was 
established by Autism Speaks (http://www.autismtissueprogram.
org). Measuring allelic differences in mRNA splicing in brain tis-
sues is a powerful approach for uncovering splicing polymorphisms 
in ASD risk genes. For example, using this approach in human 
brain tissues, we have identified two frequent intronic SNPs in 
the dopamine D2 receptor (DRD2) that alter the splicing ratios 
between the short (D2S) and long (D2L) isoforms of the recep-
tor, which correlated with working memory and activation of the 
striatum (Zhang et al., 2007). Our laboratory is now coupling this 
allele-specific approach with high-throughput sequencing to assay 
the entire transcriptome for the presence of functional genetic vari-
ants that affect RNA expression and alternative splicing of genes 
expressed in human cortex.
Newfound genetic candidates require validation of their func-
tion at the level of cellular signaling. A more cohesive analysis of 
genetics and synaptic function can be accomplished through the 
use of inducible pluripotent stem cells derived from affected indi-
viduals, which allows an ex vivo analysis of specialized differenti-
ated cells, such as neurons, from living subjects (for review, see 
Pfannkuche et al., 2010). Advances in understanding alternative 
gene splicing have clarified the consequences of aberrant splicing 
in many neurological diseases (Cooper et al., 2009). Autism appears 
to be another disorder in which disrupted mRNA splicing possibly 
contributes to etiology, although it remains to be seen whether 
aberrant splicing is recapitulated in tissues germane to the disorder, 
such as the brain.
to be addressed in a sufficient manner. First, however, we need to 
address whether disrupted alternative CAM splicing – while critical 
to synaptic function – can be responsible for behaviors inherent 
to autism.
effect of SplIcInG on dISorder phenotype
A recent study found that several genes encoding CAMs expressed 
in cortical brain regions crucial to language development are sub-
ject to rapid evolutionary pressure specific to humans (Johnson 
et al., 2009). This finding is consistent with previous observations 
of accelerated evolution in non-coding sequences near neuronal 
CAM genes (Prabhakar et al., 2006). Alternatively spliced exons, in 
general, undergo accelerated evolution of the protein subsequences 
they encode in an inverse relationship to the frequency with which 
they are included in mature mRNA (Xing and Lee, 2005), i.e., alter-
native exons with low mRNA inclusion have a high rate of protein-
altering mutations. If one considers that alternative splicing is largely 
directed through intronic cis-acting regulatory sequences, perhaps 
subject to accelerated evolution, it is conceivable that higher muta-
tion rates in these regulatory sequences result in greater variability 
in alternative splicing, and when alternative exons are included, 
they are more likely to contain a mutation that changes the encoded 
protein. Because CAM gene expression is enriched in brain regions 
crucial for language processing, sociability, and emotion process-
ing (Johnson et al., 2009), selection pressures related to the rapid 
evolution of these genes could preferentially impact these human 
functions. In fact, CAMs were frequently identified as differentially 
expressed and alternatively spliced in human versus mouse brains, 
as shown with CNTNAP2 in the prefrontal cortex (Johnson et al., 
2009), which is directly implicated in familial autism (Arking et al., 
2008). From the studies presented in this review, one can speculate 
that the alternative splicing dysfunction must have a measurable 
effect on signaling at glutamatergic and/or GABAergic synapses in 
brain areas related to the affected behaviors, thereby producing an 
autistic phenotype. At present, quantitative and qualitative measures 
of spliceoform expression across CAM genes are lacking; neverthe-
less, the high prevalence of aberrant splicing in synaptic genes and 
their role in behaviors related to ASD demands further attention.
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It is increasingly evident that genetic variation outside of coding 
regions contributes to phenotypic diversity and disease. Now that 
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